Skip to main content
Premium Trial:

Request an Annual Quote

Mark Willig

Rosetta Genomics has appointed Mark Willig as chief commercial officer. He will be responsible for sales, marketing, and market access for the company's entire diagnostic assay portfolio, and will be reporting to President and CEO Kenneth Berlin. Willig most recently served as senior vice president of sales for CardioDx. Before his time at CardioDx, he served as executive vice president of global sales for Agendia, and has also served in various positions at Thermo Fisher Scientific, PrognostiX, Abbott, and Myriad Genetics.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.